Tags | Domains | Searches | Statistics | Options | Advanced Search
|
Tags | Domains | Searches | Statistics | Options | Advanced Search |
16 hours ago
Ever since the catastrophic failure of Pfizer's HDL-raising CETP inhibitor torcetrapib in late 2006, everyone involved has wondered just what the problem was. There was a definitely higher cardiovascular-linked death …
Tagged: cardiovascular disease
Dec 1, 2008
I’m going to write this morning about a question that actually came up among several of us at the train station this morning. I’m on a route that takes a lot of people into Cambridge, so we have a good proportion of …
Tagged: drug development
Nov 26, 2008
The pace of research has noticeably slowed today here in the US. Most industrial labs will be empty tomorrow, Friday, and through the weekend, and even the academic labs will have fewer grad students and post-docs …
Tagged: blog housekeeping
Nov 25, 2008
Avandia (rosiglitazone) has been under suspicion for the last couple of years, after data appeared suggesting a higher rate of cardiovascular problems with its use. GlaxoSmithKline has been disputing this association …
Tagged: diabetes and obesity
Nov 24, 2008
Since I was talking about Nitromed on Friday, let me mention another attempt to combine two known drugs into a new therapy. Another Cambridge company whose front doors I walk by once in a while is CombinatoRx. If …
Tagged: business and markets